CIA
TEVA icon

Concurrent Investment Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Concurrent Investment Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$385K Buy
11,370
+2,277
+25% +$75.8K ﹤0.01% 1549
2026
Q1 		$274K Buy
9,093
+921
+11% +$29.6K ﹤0.01% 1554
2025
Q4 		$255K Buy
+8,172
New +$201K ﹤0.01% 1497

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Concurrent Investment Advisors's TEVA Position: Q2 2026 in Review

Concurrent Investment Advisors increased its Teva Pharmaceuticals (TEVA) stake by 25% in Q2 2026, buying an estimated $75.8K and bringing the position to 11,370 shares worth $385K. The position accounts for ﹤0.01% of the portfolio, ranked #1549.

Concurrent Investment Advisors first reported a position in TEVA in Q4 2025 and has held it in 3 quarters since. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Concurrent Investment Advisors held 11,370 shares of Teva Pharmaceuticals worth $385K as of Q2 2026.
  • Concurrent Investment Advisors bought 2,277 Teva Pharmaceuticals shares in Q2 2026, an estimated $75.8K.
  • Teva Pharmaceuticals made up ﹤0.01% of Concurrent Investment Advisors's portfolio in Q2 2026, its #1549 holding.
  • Concurrent Investment Advisors first reported a position in Teva Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Concurrent Investment Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.